5. Conclusions
depressive, neurodegenerative diseases, treatment-resistant
NEURODEGENERATIVE DISEASES
TPS is the latest technological NIBS device that has been proven effective, safe, and sustainable for reducing depressive symptom severity in this pilot RCT. The utilization of NIBS to treat neurodegenerative diseases or neuropsychiatric symptoms is likely to be a future trend in neuroscience and clinical psychiatry. In this vein, TPS may well be considered a top-on treatment option, especially for treatment-resistant patients and those who are seeking prompt recovery. Future replication of a multi-center study may wish to adopt a double-blinded, sham-controlled RCT in order to filter out the placebo effects on a larger sample.